Form 4: Travere CFO Sells Shares After Option Exercise

Travere Therapeutics' CFO, Christopher R. Cline, exercised stock options and sold 20,000 shares of common stock under a pre-arranged 10b5-1 plan.

Summary

• Christopher R. Cline, Chief Financial Officer of Travere Therapeutics, Inc. (TVTX), executed a pre-arranged transaction on December 1, 2025.
• Exercised employee stock options to acquire 20,000 shares of common stock at an exercise price of $16.23 per share.
• Immediately sold 20,000 shares of common stock at a weighted average price of $35.0101 per share, with prices ranging from $34.64 to $35.41.
• The sale was conducted under a Rule 10b5-1(c) plan adopted on May 28, 2025.
• Following these transactions, Mr. Cline directly beneficially owns 92,083 shares of common stock and no derivative securities.
• The stock option exercised was granted on May 19, 2016, fully vested, and had an expiration date of May 19, 2026.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It's a routine, pre-planned transaction for an officer to realize value from compensation, which is a positive for the individual. For the company, it's a neutral event as it doesn't indicate new strategic direction or performance.

Positives

• The Chief Financial Officer successfully monetized vested employee stock options, realizing a profit from the difference between the exercise price ($16.23) and the sale price ($35.0101).
• The transaction was executed under a pre-arranged Rule 10b5-1 plan, indicating a structured approach to managing personal equity holdings and reducing potential concerns about opportunistic insider trading.

Negatives

• An officer's sale of shares, even if pre-planned, can sometimes be perceived by some investors as a lack of confidence, although this is a routine compensation-related transaction.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This is a routine insider transaction report (Form 4) detailing an officer's exercise of stock options and subsequent sale of shares. Such transactions are common for executives managing their personal equity holdings and compensation, and do not typically reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The transaction is a routine insider sale under a pre-arranged plan, which typically has minimal direct impact on other shareholders. It represents an officer monetizing vested compensation.

Key Dates

Recommendation

This Form 4 reports a routine, pre-planned insider transaction involving the exercise of vested stock options and the subsequent sale of shares. Such transactions, especially when executed under a Rule 10b5-1 plan, are typically for personal financial planning purposes and do not inherently signal a change in the company's fundamental outlook or management's confidence. Therefore, it does not provide new information that would warrant a change in an investment recommendation based solely on this filing.

Keywords

Travere Therapeutics, TVTX, Form 4, Insider Trading, Stock Option Exercise, Share Sale, CFO, Christopher R. Cline, 10b5-1 Plan